Athenahealth to acquire mobile health app provider
WATERTOWN, Mass. — A company that provides cloud-based electronic health record, practice management and care-coordination services is buying a developer of point-of-care mobile health applications for physicians.
Athenahealth announced Monday that it would buy Epocrates for about $293 million, or $11.75 per share. The deal for Epocrates, used by more than 330,000 physicians, is expected to close in second quarter 2013, pending approval from Epocrates’ shareholders and other conditions.
"I have been an admirer of Epocrates since it first emerged and have watched the company grow consistently, one app download at a time, as it has cemented itself in to the consciousness of America’s physicians," Athenahealth president, chairman and CEO Jonathan Bush said. "No other company has been able to replicate the brand awareness, familiarity and trust that Epocrates has across the clinical mobile user base."
Prasco launches authorized generic version of Lysteda
CINCINNATI, Ohio — Drug maker Prasco Labs has launched an authorized generic version of a drug used to treat heavy menstrual bleeding, the company said Monday.
Prasco announced the launch of tranexamic acid tablets in the 650 mg strength, an authorized generic version of Ferring Pharmaceuticals’ Lysteda. Authorized generics are branded drugs marketed under their generic names at a discount, usually through third-party companies, to compete with Food and Drug Administration-approved generics.
"We are pleased to welcome Ferring Pharmaceuticals into Prasco’s family of brand partners with the introduction of the authorized generic of Lysteda tablets," Prasco CEO Chris Arington said. "With the choice of tranexamic acid tablets, customers benefit from the same consistent supply and quality of the brand they are accustomed to."
Biogen Idec hopes treatment will be first advance in hemophilia B treatment in 15 years
WESTON, Mass. — Biogen Idec is seeking Food and Drug Administration approval for a hemophilia drug that it called the first of its kind.
The drug maker announced that it had submitted a regulatory application for recombinant factor IX Fc fusion protein, or rFIXFc, which it called the first long-lasting factor IX therapy for hemophilia B.
"The submission to FDA of rFIXFc is an important milestone towards the introduction of a long-lasting factor IX therapy, which is the first major treatment advance for the hemophilia B community in 15 years," Biogen Idec SVP global medical affairs and chief medical officer for the company’s hemophilia therapeutic area Glenn Pierce said. "Our Fc fusion technology uses a natural pathway in the body to keep factor in circulation longer."